AR044147A1 - Formulaciones liquidas de interferon estabilizadas y libres de hsa - Google Patents
Formulaciones liquidas de interferon estabilizadas y libres de hsaInfo
- Publication number
- AR044147A1 AR044147A1 ARP040101486A ARP040101486A AR044147A1 AR 044147 A1 AR044147 A1 AR 044147A1 AR P040101486 A ARP040101486 A AR P040101486A AR P040101486 A ARP040101486 A AR P040101486A AR 044147 A1 AR044147 A1 AR 044147A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition according
- hsa
- free
- stabilized
- interfer
- Prior art date
Links
- 239000012669 liquid formulation Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 abstract 3
- 102000014150 Interferons Human genes 0.000 abstract 3
- 108010050904 Interferons Proteins 0.000 abstract 3
- 229940079322 interferon Drugs 0.000 abstract 3
- 239000003963 antioxidant agent Substances 0.000 abstract 2
- 230000003078 antioxidant effect Effects 0.000 abstract 2
- 239000000022 bacteriostatic agent Substances 0.000 abstract 2
- 239000000872 buffer Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000004094 surface-active agent Substances 0.000 abstract 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 102100026720 Interferon beta Human genes 0.000 abstract 1
- 108090000467 Interferon-beta Proteins 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 239000008351 acetate buffer Substances 0.000 abstract 1
- 235000019445 benzyl alcohol Nutrition 0.000 abstract 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical group OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920001993 poloxamer 188 Polymers 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describe una composición farmacéutica líquida libre de HSA y estabilizada, que comprende un interferón (INF), en donde dicha formulación es una solución que comprende un amortiguante, un surfactante, un agente de isotonicidad y un antioxidante. En forma preferida, el interferón es IFN-beta recombinante humano. Reivindicación 9: La composición de acuerdo con cualquiera de las reivindicaciones precedentes, en donde el amortiguante es amortiguante acetato. Reivindicación 10: La composición de acuerdo con cualquiera de las reivindicaciones precedentes, en donde dicho agente de isotonicidad es manitol. Reivindicación 14: La composición de acuerdo con cualquiera de las reivindicaciones precedentes, en donde dicho surfactante es Pluronic F68. Reivindicación 17: La composición de acuerdo con cualquiera de las reivindicaciones precedentes, en donde dicho antioxidante es metionina. Reivindicación 23: La composición de cualquiera de las reivindicaciones precedentes, que comprende además un agente bacteriostático. Reivindicación 24: La composición de acuerdo con cualquiera de las reivindicaciones precedentes, en donde dicho agente bacteriostático es alcohol de bencilo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03101210 | 2003-05-01 | ||
| US53016903P | 2003-12-17 | 2003-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044147A1 true AR044147A1 (es) | 2005-08-24 |
Family
ID=36908159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101486A AR044147A1 (es) | 2003-05-01 | 2004-04-30 | Formulaciones liquidas de interferon estabilizadas y libres de hsa |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US8309069B2 (es) |
| EP (1) | EP1617861B1 (es) |
| JP (2) | JP4870550B2 (es) |
| KR (1) | KR101116058B1 (es) |
| CN (1) | CN1816347B (es) |
| AR (1) | AR044147A1 (es) |
| AU (2) | AU2004233603B2 (es) |
| BR (1) | BRPI0410488B8 (es) |
| CA (1) | CA2521560A1 (es) |
| DK (1) | DK1617861T3 (es) |
| EA (2) | EA200800327A1 (es) |
| ES (1) | ES2417061T3 (es) |
| HR (1) | HRP20130512T1 (es) |
| IL (1) | IL171709A (es) |
| ME (1) | ME00404B (es) |
| MX (1) | MXPA05011718A (es) |
| MY (1) | MY151121A (es) |
| NO (1) | NO335674B1 (es) |
| NZ (2) | NZ566625A (es) |
| PL (1) | PL1617861T3 (es) |
| PT (1) | PT1617861E (es) |
| RS (1) | RS52869B (es) |
| SG (1) | SG159389A1 (es) |
| SI (1) | SI1617861T1 (es) |
| TW (1) | TWI272948B (es) |
| UA (2) | UA94032C2 (es) |
| WO (1) | WO2004096263A2 (es) |
| ZA (2) | ZA200508124B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004298781B2 (en) * | 2003-12-11 | 2010-04-01 | Ares Trading S.A. | Stabilized interferon liquid formulations |
| UA88300C2 (ru) * | 2004-05-17 | 2009-10-12 | Эйрес Трейдинг С.А. | Гидрогелевые композиции, которые содержат интерферон |
| MXPA06014079A (es) * | 2004-06-01 | 2007-02-15 | Ares Trading Sa | Metodo para estabilizar proteinas. |
| EA010979B1 (ru) * | 2004-06-01 | 2008-12-30 | Арес Трейдинг С.А. | Стабилизированные жидкие препаративные формы интерферона |
| ES2378686T3 (es) * | 2005-09-14 | 2012-04-17 | Ares Trading S.A. | Método para la determinación de poloxámeros |
| CA2649810A1 (en) | 2006-05-24 | 2007-11-29 | Laboratoires Serono S.A. | Cladribine regimen for treating multiple sclerosis |
| WO2008066322A1 (en) * | 2006-11-28 | 2008-06-05 | Daewoong Co., Ltd. | A stable hsa-free and antioxidant-free pharmaceutical composition comprising interferon-beta |
| WO2008065752A1 (fr) * | 2006-11-30 | 2008-06-05 | National University Corporation Hokkaido University | Agent immunothérapeutique contenant un arndi en tant que principe actif |
| EP2134353B1 (en) * | 2007-03-30 | 2016-11-16 | Helix Biopharma Corp. | Biphasic lipid-vesicle composition and method for treating cervical dysplasia by intravaginal delivery |
| WO2008145323A1 (en) * | 2007-05-31 | 2008-12-04 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation for interferons |
| BRPI0821029A2 (pt) * | 2007-12-20 | 2015-06-16 | Merck Serono Sa | Fomulações de peg-interferon-beta |
| KR20150074167A (ko) | 2012-10-26 | 2015-07-01 | 루핀 리미티드 | Ｐｅｇ 인터페론 알파-2ｂ의 안정한 약학 조성물 |
| US10159646B2 (en) | 2013-08-12 | 2018-12-25 | Altum-Avro Pharma Partnership | Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery |
| US8986732B2 (en) | 2013-08-12 | 2015-03-24 | Helix Biopharma Corporation | Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery |
| EP3200767A1 (en) * | 2014-09-23 | 2017-08-09 | F.Hoffmann-La Roche Ag | Stable, benzyl alcohol-free aqueous solution formulations containing alpha-type interferon |
| US9937223B2 (en) | 2015-01-30 | 2018-04-10 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9687526B2 (en) | 2015-01-30 | 2017-06-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9744239B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9744209B2 (en) | 2015-01-30 | 2017-08-29 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9925233B2 (en) | 2015-01-30 | 2018-03-27 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| US9750785B2 (en) | 2015-01-30 | 2017-09-05 | Par Pharmaceutical, Inc. | Vasopressin formulations for use in treatment of hypotension |
| KR101943160B1 (ko) * | 2016-10-06 | 2019-01-30 | 에이비온 주식회사 | 인터페론 베타 변이체의 안정화 제제 |
| CN119097635A (zh) | 2017-11-24 | 2024-12-10 | 默克专利股份公司 | 用于治疗进展型形式的多发性硬化症的克拉屈滨疗法 |
| US20240226284A1 (en) | 2020-09-10 | 2024-07-11 | Merck Patent Gmbh | Novel treatment regimen for the treatment of autoimmune disorders |
| KR20240118230A (ko) * | 2023-01-26 | 2024-08-05 | 에이비온 주식회사 | 인터페론 베타 건조 분말 제제 및 이의 제조방법 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
| US5017691A (en) | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
| US4879111A (en) | 1986-04-17 | 1989-11-07 | Cetus Corporation | Treatment of infections with lymphokines |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| IT1272252B (it) * | 1994-05-16 | 1997-06-16 | Applied Research Systems | Formulazioni liquide di interferone beta |
| TW426523B (en) | 1995-04-06 | 2001-03-21 | Hoffmann La Roche | Interferon solution |
| ZA9610374B (en) * | 1995-12-11 | 1997-06-23 | Elan Med Tech | Cartridge-based drug delivery device |
| SI0948358T2 (sl) * | 1996-12-24 | 2012-03-30 | Biogen Idec Inc | Stabilne tekoče formulacije interferona |
| US6013253A (en) | 1997-08-15 | 2000-01-11 | Amgen, Inc. | Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist |
| DK1017413T4 (da) * | 1997-09-23 | 2008-03-25 | Rentschler Biotech Gmbh | Flydende formulering af interferon-beta |
| WO1999029863A1 (en) * | 1997-12-08 | 1999-06-17 | Genentech, Inc. | Human interferon-epsilon: a type i interferon |
| TR200101751T2 (tr) | 1998-04-28 | 2002-05-21 | Applied Research Systems Ars Holding N.V. | Poliol-IFN-beta konjugatları |
| PT1852424E (pt) * | 1998-05-11 | 2012-05-07 | Basf Se | Processo para a preparação de isoxazolino-3-ilacilbenzenos |
| CN1175901C (zh) * | 1999-12-06 | 2004-11-17 | 天津华立达生物工程有限公司 | 一种稳定的干扰素水溶液 |
| US6465425B1 (en) * | 2000-02-10 | 2002-10-15 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins |
| US6887462B2 (en) | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
| UY27373A1 (es) * | 2001-07-09 | 2003-02-28 | Schering Ag | Formulaciones de interferón beta-humano |
| AU2004298781B2 (en) * | 2003-12-11 | 2010-04-01 | Ares Trading S.A. | Stabilized interferon liquid formulations |
| UA88300C2 (ru) * | 2004-05-17 | 2009-10-12 | Эйрес Трейдинг С.А. | Гидрогелевые композиции, которые содержат интерферон |
| MXPA06014079A (es) * | 2004-06-01 | 2007-02-15 | Ares Trading Sa | Metodo para estabilizar proteinas. |
-
2004
- 2004-04-23 TW TW093111368A patent/TWI272948B/zh not_active IP Right Cessation
- 2004-04-29 KR KR1020057020444A patent/KR101116058B1/ko not_active Expired - Lifetime
- 2004-04-29 ES ES04730264T patent/ES2417061T3/es not_active Expired - Lifetime
- 2004-04-29 HR HRP20130512TT patent/HRP20130512T1/hr unknown
- 2004-04-29 EA EA200800327A patent/EA200800327A1/ru unknown
- 2004-04-29 MY MYPI20041605 patent/MY151121A/en unknown
- 2004-04-29 RS YU20050821A patent/RS52869B/sr unknown
- 2004-04-29 CN CN2004800188759A patent/CN1816347B/zh not_active Expired - Lifetime
- 2004-04-29 SI SI200432066T patent/SI1617861T1/sl unknown
- 2004-04-29 AU AU2004233603A patent/AU2004233603B2/en not_active Expired
- 2004-04-29 SG SG200705206-1A patent/SG159389A1/en unknown
- 2004-04-29 UA UAA200704143A patent/UA94032C2/ru unknown
- 2004-04-29 UA UAA200509798A patent/UA80331C2/uk unknown
- 2004-04-29 ZA ZA200508124A patent/ZA200508124B/xx unknown
- 2004-04-29 US US10/554,602 patent/US8309069B2/en active Active
- 2004-04-29 WO PCT/EP2004/004806 patent/WO2004096263A2/en not_active Ceased
- 2004-04-29 EP EP04730264.1A patent/EP1617861B1/en not_active Expired - Lifetime
- 2004-04-29 PT PT47302641T patent/PT1617861E/pt unknown
- 2004-04-29 DK DK04730264.1T patent/DK1617861T3/da active
- 2004-04-29 EA EA200501699A patent/EA009995B1/ru not_active IP Right Cessation
- 2004-04-29 NZ NZ566625A patent/NZ566625A/en not_active IP Right Cessation
- 2004-04-29 JP JP2006505383A patent/JP4870550B2/ja not_active Expired - Lifetime
- 2004-04-29 MX MXPA05011718A patent/MXPA05011718A/es active IP Right Grant
- 2004-04-29 NZ NZ542912A patent/NZ542912A/en not_active IP Right Cessation
- 2004-04-29 CA CA002521560A patent/CA2521560A1/en not_active Withdrawn
- 2004-04-29 ME MEP-2008-604A patent/ME00404B/me unknown
- 2004-04-29 PL PL04730264T patent/PL1617861T3/pl unknown
- 2004-04-29 BR BRPI0410488A patent/BRPI0410488B8/pt not_active IP Right Cessation
- 2004-04-30 AR ARP040101486A patent/AR044147A1/es not_active Application Discontinuation
-
2005
- 2005-11-01 IL IL171709A patent/IL171709A/en active IP Right Grant
- 2005-11-30 NO NO20055666A patent/NO335674B1/no unknown
-
2007
- 2007-10-04 ZA ZA200708484A patent/ZA200708484B/xx unknown
-
2009
- 2009-03-31 AU AU2009201261A patent/AU2009201261A1/en not_active Abandoned
-
2011
- 2011-07-15 JP JP2011156524A patent/JP5346065B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA94032C2 (ru) | Жидкая стабализированная композиция интерферона без hsa | |
| BR9813463A (pt) | Soluções de teriparatida estabilizadas | |
| PE38897A1 (es) | Solucion acuosa de interferon alfa | |
| ATE522200T1 (de) | Aripiprazole injektionsuspension | |
| DK1792610T3 (da) | Terapeutiske bioadhæsive systemet med langvarig frigivelse | |
| AR049635A1 (es) | (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c | |
| ES2131781T3 (es) | Formulacion estable liofilizada que comprende una proteina, equipo de dosificacion. | |
| ATE471144T1 (de) | Intranasale verabreichung von schnell wirkendem insulin | |
| BR0008405A (pt) | Composição de fator viii formulada sem a adição de albumina, uso de uma composição de fator viii, e, método de liofilizar uma formulação farmacêutica aquosa | |
| ATE433746T1 (de) | Insulinzusammensetzungen mit verbesserter wirkstoffabsorption | |
| BR0112962A (pt) | Composições farmacêuticas para o tratamento de condições inflamatórias e ulcerativas dolorosas de maioria das superfìcies epiteliais tais como mucosite, estomatite e sìndrome de behcet | |
| CY1110352T1 (el) | Αντι-ιικος παραγοντας υπο τη μορφη ρινικων σταγονων | |
| UY27378A1 (es) | Composición farmacéutica | |
| HRP20100727T1 (hr) | Tekući ili liofilizirani farmaceutski pripravci fsh i/ili lh zajedno s neionskim tenzidom poloksamer 188 i bakteriostatskim sredstvom | |
| ATE526032T1 (de) | Stabilisierte flüssige interferon-formulierungen | |
| DE60036199D1 (de) | Proteaseresistente flint-analoge | |
| MX9207344A (es) | Formulaciones mejoradas que tienen mejoradores hidrofobicos de penetracion transdermica y metodo para proveerla. | |
| AR040600A1 (es) | Composicion farmaceutica estable que comprende eritropoietina | |
| RU2000101894A (ru) | Лекарственный гель | |
| BR0202759A (pt) | Composição farmacêutica de liberação modificada contendo bupropiona como substância ativa | |
| ECSP982775A (es) | Soluciones teriparatidas estabilizadas | |
| FI20020121A0 (fi) | Peptidit vastustuskyvyn parantamiseksi mikrobi-infektioita vastaan |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |